ABSTRACT Cardiovascular adverse events (CVAEs) associated with bispecific T‐cell engaging antibodies (BsAbs) have not been systematically investigated across approved agents. In this disproportionality analysis of FAERS (December 2014–September 2025), reports listing BsAbs as the primary suspected drug (n = 7647) were compared with all other drugs in ...
Malak Munir +9 more
wiley +1 more source
Breast Mass as an Atypical Presentation of Non-Hodgkin Lymphoma. [PDF]
Figueiredo F +4 more
europepmc +1 more source
A Multi-Targeted Strategy for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: Real-World Outcomes of the ViPOR Regimen. [PDF]
Yiğit Kaya S +7 more
europepmc +1 more source
Secondary primary malignancies in indolent non-Hodgkin lymphoma patients receiving frontline bendamustine-rituximab. [PDF]
Davies GA +7 more
europepmc +1 more source
[Hodgkin lymphoma and non-Hodgkin lymphoma].
openaire +2 more sources
Quantitative longitudinal photoacoustic imaging of vascular oxygenation for therapy response monitoring in Non-Hodgkin lymphoma. [PDF]
Shi J +7 more
europepmc +1 more source
Pediatric Mediastinal Gray Zone Lymphoma With Germline TET2 Heterozygous Variant
Pediatric Blood &Cancer, Volume 73, Issue 11, November 2026.
Matthew R. Schuelke +9 more
wiley +1 more source
NEK2 drives pathogenesis, drug resistance, and LMP1 expression in EBV-positive non-Hodgkin lymphoma. [PDF]
White MC +3 more
europepmc +1 more source
Primary extranodal marginal zone non-hodgkin lymphoma of the prostate: a case report. [PDF]
Gao X, Wang X, Wang X, Cai H.
europepmc +1 more source
Geospatial Access to CAR-T Clinical Trials for Non-Hodgkin Lymphoma for Persons With HIV.
Maillie L +8 more
europepmc +1 more source

